Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasms
NCT04992949Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by French Innovative Leukemia Organisation. Started Mar 2022; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04992949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04992949.